Compounds > cyc 202
Page last updated: 2024-09-04

cyc 202 and bs 194

cyc 202 has been researched along with bs 194 in 3 studies

Compound Research Comparison

Studies
(cyc 202)		Trials
(cyc 202)		Recent Studies (post-2010)
(cyc 202)		Studies
(bs 194)		Trials
(bs 194)		Recent Studies (post-2010) (bs 194)
97973931109

Protein Interaction Comparison

ProteinTaxonomycyc 202 (IC50)bs 194 (IC50)
Chain A, Cell division protein kinase 2Homo sapiens (human)0.003
Cyclin-T1Homo sapiens (human)0.06
Cyclin-dependent kinase 1Homo sapiens (human)0.033
Insulin receptor-related proteinHomo sapiens (human)1.8
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.033
G1/S-specific cyclin-E1Homo sapiens (human)0.003
Cyclin-dependent kinase 2Homo sapiens (human)0.003
Mitogen-activated protein kinase 3 Homo sapiens (human)3.73
Mitogen-activated protein kinase 1Homo sapiens (human)3.11
Casein kinase I isoform alphaHomo sapiens (human)1.04
Cyclin-dependent kinase 8Homo sapiens (human)0.09
Cyclin-dependent kinase 7Homo sapiens (human)0.25
Cyclin-dependent kinase 9Homo sapiens (human)0.09
Cyclin-HHomo sapiens (human)0.25
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.03
Dual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)2.1
Mitogen-activated protein kinase 15Homo sapiens (human)0.33
Calcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)2.45

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Aboagye, EO; Ali, S; Alikian, M; Barbazanges, M; Barrett, AG; Blum, A; Brackow, J; Coombes, RC; Freemont, PS; Fuchter, MJ; Hazel, P; Heathcote, DA; Jogalekar, AS; Kanneganti, SK; Kroll, SH; Liotta, DC; Pace, RD; Patel, H; Periyasamy, M; Scheiper, B; Siwicka, A; Snyder, JP1
de Dios, A; Lallena, MJ; Sánchez-Martínez, C; Sanfeliciano, SG1
George, RF; Georgey, HH; Hassan, GS; Mahmoud, WR; Mohammed, EZ; Omar, FA1

Reviews

1 review(s) available for cyc 202 and bs 194

ArticleYear
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).
    Bioorganic & medicinal chemistry letters, 2019, 10-15, Volume: 29, Issue:20

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Cycle Checkpoints; Cyclin-Dependent Kinases; Drug Discovery; Humans; Indoles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Transcription Factors

2019

Other Studies

2 other study(ies) available for cyc 202 and bs 194

ArticleYear
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.
    Journal of medicinal chemistry, 2010, Dec-23, Volume: 53, Issue:24

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Blood Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 9; Female; Humans; In Vitro Techniques; Mice; Mice, Nude; Microsomes, Liver; Models, Molecular; Phosphorylation; Protein Binding; Pyrazoles; Pyrimidines; Stereoisomerism; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2010
Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors.
    European journal of medicinal chemistry, 2021, Jun-05, Volume: 218

    Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cyclin-Dependent Kinase 2; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quantitative Structure-Activity Relationship

2021